Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Feb 28;147(9):743-745.
doi: 10.1161/CIRCULATIONAHA.122.063495. Epub 2023 Feb 27.

Targeting ADAMTS-7: A Vaccination Against Atherosclerosis-and Its Complications?

Thorsten Kessler  1 , Heribert Schunkert  1
Affiliations
Editorial

Targeting ADAMTS-7: A Vaccination Against Atherosclerosis-and Its Complications?

Thorsten Kessler et al. Circulation. .
No abstract available

Keywords: Editorials; atherosclerosis; coronary artery disease; vaccination.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures

T.K. received lecture fees from Bayer, Abbott, and Astra-Zeneca which are unrelated to this work. H.S. received personal fees from MSD SHARP & DOHME, AMGEN, Bayer Vital GmbH, Boehringer Ingelheim, Daiichi-Sankyo, Novartis, Servier, Brahms, Bristol-Myers-Squibb, Medtronic, Sanofi Aventis, Synlab, Pfizer, and Vifor T as well as grants and personal fees from Astra-Zeneca which are unrelated to this work. The authors are named inventors on a patent application for prevention of restenosis after angioplasty and stent implantation which is unrelated to this work.

Figures

Figure 1
Figure 1. ADAMTS-7 vaccination.
ADAMTS-7 expression and activity in vascular smooth muscle cells were found to be increased by a variety of stimuli. ADAMTS-7 modulates atherosclerosis and neointima formation through several known but also unexplored pathways. Vaccination against ADAMTS-7 (ATS7vac) using an ADAMTS-7 epitope leads to the generation of anti-ADAMTS-7 antibodies by B cells. This approach could be used in primary prevention to ameliorate atherosclerotic plaque formation or in patients treated with stents for reducing neointima formation via the inhibition of ADAMTS-7 and its downstream effects.
See this image and copyright information in PMC

Comment on

References

    1. Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, Weeks EM, Wang M, Hindy G, Zhou W, et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. Nat Genet. 2022;54:1803–1815. - PMC - PubMed
    1. Chyu K-Y, Shah PK. In pursuit of an atherosclerosis vaccine. Circ Res. 2018;123:1121–1123. - PubMed
    1. Nilsson J, Hansson GK. Vaccination strategies and immune modulation of atherosclerosis. Circ Res. 2020;126:1281–1296. - PubMed
    1. Ma Z, Mao C, Chen X, Yang S, Qiu Z, Yu B, Jia Y, Wu C, Wang Y, Wang Y, et al. A peptide vaccine against ADAMTS-7 ameliorates atherosclerosis and postinjury neointima hyperplasia. Circulation. In press. - PubMed
    1. Reilly MP, Li M, He J, Ferguson JF, Stylianou IM, Mehta NN, Burnett MS, Devaney JM, Knouff CW, Thompson JR, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet. 2011;377:383–392. - PMC - PubMed

Substances